Literature DB >> 30862547

Highly Multiplexed Fluorescence in Situ Hybridization for in Situ Genomics.

Maristela L Onozato1, Clarence Yapp2, Douglas Richardson3, Tilak Sundaresan4, Varun Chahal1, Jesse Lee1, James P Sullivan4, Marisa W Madden4, Hyo S Shim5, Matthew Liebers1, Quan Ho1, Shyamala Maheswaran4, Daniel A Haber4, Zongli Zheng1, Brian Clancy6, Hunter L Elliott2, Jochen K Lennerz7, A John Iafrate8.   

Abstract

The quantification of changes in gene copy number is critical to our understanding of tumor biology and for the clinical management of cancer patients. DNA fluorescence in situ hybridization is the gold standard method to detect copy number alterations, but it is limited by the number of genes one can quantify simultaneously. To increase the throughput of this informative technique, a fluorescent bar-code system for the unique labeling of dozens of genes and an automated image analysis algorithm that enabled their simultaneous hybridization for the quantification of gene copy numbers were devised. We demonstrate the reliability of this multiplex approach on normal human lymphocytes, metaphase spreads of transformed cell lines, and cultured circulating tumor cells. It also opens the door to the development of gene panels for more comprehensive analysis of copy number changes in tissue, including the study of heterogeneity and of high-throughput clinical assays that could provide rapid quantification of gene copy numbers in samples with limited cellularity, such as circulating tumor cells.
Copyright © 2019 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30862547      PMCID: PMC6504678          DOI: 10.1016/j.jmoldx.2019.01.010

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  36 in total

1.  Cryptic translocation identification in human and mouse using several telomeric multiplex fish (TM-FISH) strategies.

Authors:  O Henegariu; S Artan; J M Greally; X N Chen; J R Korenberg; G H Vance; L Stubbs; P Bray-Ward; D C Ward
Journal:  Lab Invest       Date:  2001-04       Impact factor: 5.662

2.  New strategy for multi-colour fluorescence in situ hybridisation: COBRA: COmbined Binary RAtio labelling.

Authors:  H J Tanke; J Wiegant; R P van Gijlswijk; V Bezrookove; H Pattenier; R J Heetebrij; E G Talman; A K Raap; J Vrolijk
Journal:  Eur J Hum Genet       Date:  1999-01       Impact factor: 4.246

Review 3.  Gene amplification in cancer.

Authors:  Donna G Albertson
Journal:  Trends Genet       Date:  2006-06-19       Impact factor: 11.639

4.  Glioblastoma survival in the United States before and during the temozolomide era.

Authors:  Derek R Johnson; Brian Patrick O'Neill
Journal:  J Neurooncol       Date:  2011-11-02       Impact factor: 4.130

5.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

Review 6.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.

Authors:  L A Stewart
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

Review 7.  Copy number variations and cancer susceptibility.

Authors:  Adam Shlien; David Malkin
Journal:  Curr Opin Oncol       Date:  2010-01       Impact factor: 3.645

8.  A novel multiple FISH array for the detection of genetic aberrations in cancer.

Authors:  Ruiyun Li; Zhenqiu Liu; Tao Fan; Feng Jiang
Journal:  Lab Invest       Date:  2006-06       Impact factor: 5.662

9.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Authors:  James J Vredenburgh; Annick Desjardins; James E Herndon; Jennifer Marcello; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Melissa Wagner; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

10.  Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data.

Authors:  Michael Baudis
Journal:  BMC Cancer       Date:  2007-12-18       Impact factor: 4.430

View more
  3 in total

Review 1.  Pediatric Sarcomas: The Next Generation of Molecular Studies.

Authors:  Petros Giannikopoulos; David M Parham
Journal:  Cancers (Basel)       Date:  2022-05-20       Impact factor: 6.575

2.  Somatic Focal Copy Number Gains of Noncoding Regions of Receptor Tyrosine Kinase Genes in Treatment-Resistant Epilepsy.

Authors:  Varshini Vasudevaraja; Javier Hernaez Rodriguez; Cristiana Pelorosso; Kaicen Zhu; Anna Maria Buccoliero; Maristela Onozato; Hussein Mohamed; Jonathan Serrano; Lily Tredwin; Marianna Garonzi; Claudio Forcato; Briana Zeck; Sitharam Ramaswami; James Stafford; Arline Faustin; Daniel Friedman; Eveline Teresa Hidalgo; David Zagzag; Jane Skok; Adriana Heguy; Luis Chiriboga; Valerio Conti; Renzo Guerrini; A John Iafrate; Orrin Devinsky; Aristotelis Tsirigos; John G Golfinos; Matija Snuderl
Journal:  J Neuropathol Exp Neurol       Date:  2021-01-20       Impact factor: 3.685

Review 3.  Tracking cancer progression: from circulating tumor cells to metastasis.

Authors:  Francesc Castro-Giner; Nicola Aceto
Journal:  Genome Med       Date:  2020-03-19       Impact factor: 11.117

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.